Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy

European Respiratory Journal

Volumn 36, Issue 3, 2010, Pages 524-530

  Aubier, M ^a   Buhl, R ^c   Ekstrom T ^d   Ostinelli, J ^b   Van Schayck, C P ^f,g   Selroos, O ^e   Haughney, J ^h  

^a BICHAT HOSPITAL   (France)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d ASTRAZENECA R AND D   (Sweden)

^e Semeco   (Sweden)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Asthma; Budesonide formoterol; Exacerbations; Maintenance and reliever therapy; Predictive factors; Symbicort SMART

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; LONG ACTING DRUG; SYMBICORT SMART; TERBUTALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG FUNCTION; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BUDESONIDE; DRUG ADMINISTRATION SCHEDULE; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; RESEARCH DESIGN; TIME FACTORS;

EID: 77956600926     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00022010     Document Type: Article

References (21)

1. Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 2007; 23: 1867-1878.
2. 2-agonist and inhaled corticosteroid. Ther Clin Risk Manag 2007; 3: 349-359.
3. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136. (Pubitemid 40105411)
4. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418. (Pubitemid 39361344)
5. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest 2006; 129: 246-256.
6. Bateman ED, Bantje TA, João Gomes M, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med 2003; 2: 275-281.
7. Rabe KF, Atienza T, Larsson P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753. (Pubitemid 44279053)
8. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-736. (Pubitemid 46587876)
9. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-828.
10. Bousquet J, Boulet L-P, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007; 101: 2437-2446. (Pubitemid 350010579)
11. Bateman ER, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma controL study. Am J Respir Crit Care Med 2004; 170: 836-844. (Pubitemid 39346477)
12. Lundborg M, Wille S, Bjermer L, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006; 22: 809-821. (Pubitemid 43875550)
13. American Thoracic Society (ATS). Standards for the diagnosis and care of subjects with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
14. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907. (Pubitemid 29519356)
15. Svensson K, Mörk AC, Juniper EF. ACQ. Is five out of seven items acceptable in large clinical studies? Qual Life Res 2003; 12: 771.
16. Juniper EF, Bousquet J, Abetz L, et al. Identifying "well- controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621.
17. Global Initiative for Asthma. GINA Report: global strategy for asthma management and prevention. www.ginasthma.com/download.asp?intld=343 Date last accessed: December 16, 2009. Last updated 2009.
18. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009; 103: 1960-1968.
19. Schreurs AJ, Sinninghe Damste HE, de Graaff CS, et al. A dose-response study with formoterol Turbuhaler1 as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9: 1678-1683.
20. Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol maintenance and reliever asthma therapy. Allergy 2007; 62: 1189-1198. (Pubitemid 47374022)
21. Ställberg B, Ekström T, Neij F, et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respir Med 2008; 102: 1360-1370.